Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627409 | 0.98 | MAPT (0.46) | MAPTGAAALDH1A1LMNAHTT | |
| SCHEMBL19627415 | 0.98 | MAPT (0.46) | MAPTGAAALDH1A1LMNAHTT | |
| SCHEMBL27021617 | 0.96 | MAPT (0.40) | MAPTGAAALDH1A1LMNAHTT | |
| SCHEMBL13712256 | 0.85 | CYP1A2 (0.38) | MAPTGAAALDH1A1LMNATSHR | |
| SCHEMBL27021615 | 0.83 | MEN1 (0.45) | KMT2ATSHR | |
| SCHEMBL19627403 | 0.82 | CYP2D6 (0.36) | MAPTGAAALDH1A1LMNAHTT | |
| SCHEMBL19627364 | 0.78 | GAA (0.48) | MAPTGAAKMT2AFKBP1ATSHR | |
| SCHEMBL19627367 | 0.77 | GAA (0.50) | MAPTGAAKMT2AFKBP1ATSHR | |
| SCHEMBL19627386 | 0.77 | GAA (0.50) | MAPTGAAKMT2AFKBP1ATSHR | |
| SCHEMBL19630970 | 0.77 | GAA (0.45) | MAPTGAAALDH1A1KMT2AFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287029-A1 | SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | CHENGDU SHIBEIKANG BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-4410786-A1 | SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023046150-A1 | SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都施贝康生物医药科技有限公司 | 2023-03-30 | — | — | WO | disclosed |
| CN-113773300-B | Sulfonamide compound, preparation method and application thereof | 成都施贝康生物医药科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287029-A1 | SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | P2RX3, P2RX5, P2RX2 | MAPT 4605/4885GAA 1521/4885ALDH1A1 2252/4885 |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | SLC10A1, FXR1, SLC10A2 | MAPT 3933/4885GAA 892/4885ALDH1A1 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.